Cingulate Inc. (CINGW)Kansas City, United States | NasdaqCM
0.02 USD
+0.00
(6.881%)
⇧
(July 13, 2026, 3:50 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:22 a.m. EDT
The immediate outlook is severely clouded by a massive 20% reverse stock split initiated to preserve a Nasdaq listing, signaling extreme distress and a desperate attempt to meet minimum price requirements rather than organic growth. This mechanical adjustment often precedes significant volatility and dilution, making a near-term bullish entry highly speculative. Looking further ahead, the business fundamentals are catastrophic: the company is burning through cash with negative operating and free cash flows, posting double-digit negative returns on both assets and equity, and carrying a massive debt load relative to its tiny equity base. The price-to-book ratio is mathematically distorted by the reverse split and negative earnings, rendering traditional valuation metrics useless. With no dividend history and a trajectory defined by continuous capital destruction, this security represents a value trap where the market has correctly priced in the likelihood of insolvency or delisting. The statistical forecasting model suggests a potential 20% gain over the next 45 days, but given the 'very low' confidence rating and the chaotic nature of penny stocks undergoing reverse splits, this signal is noise rather than a predictive edge. Investors should avoid this instrument entirely. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 39.38 |
| Beta | -0.92 |
| Website | https://www.cingulate.com |
| Attribute | Value |
|---|---|
| Address1 | 1,901 West 47th Place |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | -0.915 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | 1.584 |
| City | Kansas City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0233 |
| Current Ratio | 2.547 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.0233 |
| Day Low | 0.0233 |
| Debt To Equity | 39.38 |
| Display Name | Cingulate |
| Ebitda | -23,658,508 |
| Ebitda Margins | 0.0 |
| Eps Trailing Twelve Months | -1.732 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.0233 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.0233 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.0233 - 0.0233 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,783,690,200,000 |
| Float Shares | 12,944,387 |
| Free Cashflow | -11,919,704 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -9,735,749 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,021-12-08 |
| Language | en-US |
| Long Business Summary | Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas. |
| Long Name | Cingulate Inc. |
| Market | us_market |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1674914781 |
| Net Income To Common | -27,909,322 |
| Open | 0.0385 |
| Operating Cashflow | -19,549,860 |
| Operating Margins | 0.0 |
| Phone | 913 942 2300 |
| Previous Close | 0.0218 |
| Price Hint | 4 |
| Price To Book | 0.014709596 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.373 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0014999993 |
| Regular Market Change Percent | 6.8807306 |
| Regular Market Day High | 0.0233 |
| Regular Market Day Low | 0.0233 |
| Regular Market Day Range | 0.0233 - 0.0233 |
| Regular Market Open | 0.0385 |
| Regular Market Previous Close | 0.0218 |
| Regular Market Price | 0.0233 |
| Regular Market Time | 1,783,972,251 |
| Regular Market Volume | 2,400 |
| Return On Assets | -0.69682 |
| Return On Equity | -2.2511399 |
| Sand P52 Week Change | 0.20847368 |
| Sector | |
| Sector Key | |
| Short Name | Cingulate Inc. Warrants |
| Source Interval | 15 |
| State | KS |
| Symbol | CINGW |
| Total Cash | 25,893,210 |
| Total Cash Per Share | 1.95 |
| Total Debt | 7,428,991 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.732 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 2,400 |
| Website | https://www.cingulate.com |
| Zip | 66,205 |